AGIO vs. ROIV, INSM, ASND, LEGN, CERE, ITCI, VKTX, JAZZ, BPMC, and SMMT
Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Roivant Sciences (ROIV), Insmed (INSM), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical preparations" industry.
Roivant Sciences (NASDAQ:ROIV) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings.
Roivant Sciences has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
Roivant Sciences presently has a consensus target price of $16.90, suggesting a potential upside of 63.13%. Agios Pharmaceuticals has a consensus target price of $35.00, suggesting a potential downside of 3.69%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Roivant Sciences is more favorable than Agios Pharmaceuticals.
In the previous week, Agios Pharmaceuticals had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 23 mentions for Agios Pharmaceuticals and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.24 beat Agios Pharmaceuticals' score of 0.13 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.
Agios Pharmaceuticals has lower revenue, but higher earnings than Roivant Sciences. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
64.8% of Roivant Sciences shares are owned by institutional investors. 4.6% of Roivant Sciences shares are owned by company insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Roivant Sciences has a net margin of 3,484.86% compared to Roivant Sciences' net margin of -1,199.26%. Agios Pharmaceuticals' return on equity of -31.89% beat Roivant Sciences' return on equity.
Agios Pharmaceuticals received 435 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 75.44% of users gave Roivant Sciences an outperform vote while only 67.51% of users gave Agios Pharmaceuticals an outperform vote.
Summary
Roivant Sciences beats Agios Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Agios Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agios Pharmaceuticals Competitors List
Related Companies and Tools
